GlassScriptPhysician profile
Kamylli J Mendive
NPI 1821653254
$3,903.67
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,221 · 2022: $1,540 · 2023: $115 · 2024: $26.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $432.62 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.42 | 2021-2022 | |
| Glaxosmithkline, LLC. | $417.32 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $415.15 | 2021-2022 | |
| Pfizer INC. | $414.84 | 2021-2022 | |
| Abbvie INC. | $353.94 | 2021-2024 | |
| Lilly USA, LLC | $198.47 | 2021-2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $159.42 | 2022 | |
| Radius Health, INC. | $157.79 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.76 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $121.92 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $109.00 | 2021 | |
| Novo Nordisk INC | $101.67 | 2021-2022 | |
| Astellas Pharma US INC | $74.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.30 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $56.58 | 2021-2022 | |
| Amarin Pharma, INC. | $46.04 | 2021 | |
| Acadia Pharmaceuticals INC | $37.69 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $31.44 | 2022 | |
| Philips North America LLC | $27.31 | 2021 | |
| Qiagen, LLC | $23.21 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.53 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.46 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.09 | 2022 | |
| Acerus Pharmaceuticals Corporation | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamylli Mendive listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.